Wegovy® pill approved in the US as first oral GLP-1 for weight management

• Wegovy^® pill showed a mean weight loss of 16.6% in the OASIS 4 trial
• Wegovy^® pill is indicated to reduce excess body weight and maintain weight reduction long-term and to reduce the risk of major adverse cardiovascular events*
• Novo Nordisk expects to launch Wegovy^® pill in the US in early January 2026

Dubai, 24 December 2025- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Wegovy^® pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events*.

The Wegovy^® pill is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management. The approval is based on the OASIS trial programme and the SELECT trial. In the OASIS 4 trial, oral semaglutide 25 mg taken once daily demonstrated 16.6% mean weight loss when treatment was adhered to in adult participants with obesity or overweight with one or more comorbidities¹. The weight loss achieved with the Wegovy^® pill is similar to that of injectable Wegovy^® 2.4 mg. Furthermore, one in three people experienced 20% or greater weight loss in the OASIS 4 trial¹. The well-known safety and tolerability profile of semaglutide was reaffirmed with the Wegovy^® pill in the OASIS-4 trial, which was comparable to previous trials with semaglutide for weight management.

“The pill is here. With today's approval of the Wegovy^® pill, patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy^® injection,” said Mike Doustdar, president and CEO of Novo Nordisk. “As the first oral GLP-1 treatment for people living with overweight or obesity, the Wegovy^® pill provides patients with a new, convenient treatment option that can help patients start or continue their weight loss journey. No other current oral GLP-1 treatment can match the weight loss delivered by the Wegovy^® pill, and we are very excited for what this will mean for patients in the US”.

Novo Nordisk expects to launch the Wegovy^® pill in the US in early January 2026. Novo Nordisk has submitted oral semaglutide 25 mg once-daily for obesity to the European Medicines Agency (EMA) and other regulatory authorities during the second half of 2025.